article thumbnail

New Study Suggests Pregnant Women Should Avoid Caffeine Altogether. Here’s Why

XTalks

Related: Maternal Antibodies: How Allergies Can be Passed from Mothers to Children. The results did not differ based on fast or slow caffeine metabolism genotype. Grantz, of the Division of Intramural Population Health Research at NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development.

article thumbnail

Treatment of Metastatic Triple-Negative Breast Cancer

The Pharma Data

SG is an antibody and topoisomerase inhibitor conjugate directed to the Trop-2 cell surface antigen, a protein frequently expressed in multiple types of epithelial tumors, including TNBC, where high expression is associated with poor survival and relapse. More information about ASCENT is available at [link]. Embryo-Fetal Toxicity.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AstraZeneca lung and breast cancer data at WCLC and ESMO.

The Pharma Data

Transforming treatment of advanced cancers with antibody drug conjugates (ADCs). Durvalumab ± Tremelimumab + Platinum-Etoposide in 1L ES-SCLC: Exploratory Analysis of HLA Genotype and Survival in CASPIAN. Antibody drug conjugates. Antibody drug conjugates. Lead author. Abstract title. Presentation details. Garassino, MC.

Trials 52
article thumbnail

Trodelvy® for the Treatment of Metastatic Urothelial Cancer

The Pharma Data

Accelerated Approval Granted for Locally Advanced or Metastatic Urothelial Cancer Following a Platinum-Containing Chemotherapy and a PD-1/PD-L1 Inhibitor –. – New Indication Marks Second FDA Approval for Trodelvy in 2021 –. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. FOSTER CITY, Calif.–(BUSINESS

article thumbnail

Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

The Pharma Data

Trodelvy (sacituzumab govitecan-hziy) is a first-in-class antibody and topoisomerase inhibitor conjugate directed to the Trop-2 receptor, a protein frequently expressed in multiple types of epithelial tumors, including metastatic triple-negative breast cancer (TNBC), where high expression is associated with poor survival and relapse.

HR 52